about
Therapeutic antibodies, vaccines and antibodyomesUltrahigh-throughput screening in drop-based microfluidics for directed evolution.Recent Progress towards Novel EV71 Anti-Therapeutics and VaccinesMonoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virusChallenges in Antibody Development against Tn and Sialyl-Tn AntigensStability engineering of the human antibody repertoireTumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunityTranslating basic mechanisms of IgG effector activity into next generation cancer therapiesDrugs derived from phage display: from candidate identification to clinical practiceHuman endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice?In situ click chemistry: from small molecule discovery to synthetic antibodiesAntibody Drug Conjugates: Preclinical ConsiderationsSynthetic antibodies for specific recognition and crystallization of structured RNAVariants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding siteChemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimeticA Reverse Binding Motif That Contributes to Specific Protease Inhibition by AntibodiesAtypical Antigen Recognition Mode of a Shark Immunoglobulin New Antigen Receptor (IgNAR) Variable Domain Characterized by Humanization and Structural AnalysisStructural Similarity between Defense Peptide from Wheat and Scorpion Neurotoxin Permits Rational Functional DesignCrystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumabPractical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodiesDiamond: shedding light on structure-based drug discoveryAntibody drug-conjugates targeting the tumor vasculature: Current and future developmentsDesign of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkersNanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infectionRealizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concernsThe strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicityA High Power-Density, Mediator-Free, Microfluidic Biophotovoltaic Device for Cyanobacterial CellsTherapeutic antibodies: current state and future trends--is a paradigm change coming soon?Generation of human antigen-specific monoclonal IgM antibodies using vaccinated "human immune system" miceA humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft modelsAnticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies.Technological Microbiology: Development and ApplicationsHuman IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activationExceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.Antibody humanization by structure-based computational protein design.Post-translational modifications differentially affect IgG1 conformation and receptor binding.Tryptophan-tryptophan energy transfer and classification of tryptophan residues in proteins using a therapeutic monoclonal antibody as a model.Top-down mass spectrometry for the analysis of combinatorial post-translational modifications.Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsAffinity maturation of antibodies assisted by in silico modeling.
P2860
Q24599662-97315D32-311D-47F6-B271-D5FA0E90B264Q24626072-A94622C3-E833-4AC8-AEFD-74951B9173B0Q26775734-CBDBB367-4DE2-41BB-B74C-DA47DCD42A63Q26783378-6EDF8826-B29A-4F32-90F4-BC6C3E3FA081Q26798183-C76945F7-37E5-4AB5-94C4-32D81F2213E1Q26859495-D297A99B-FEFE-42DD-A3E3-1206EB1E439EQ26862220-0814BCD6-B4EF-4B26-840C-047CBD24EA0BQ26991899-82B1EE2D-0E08-4338-9C87-31540AB2D713Q27007101-9CBD4FC2-4769-4E28-B1DC-4F1B1934BC7EQ27010373-8FB24B21-D277-434C-96C5-5B92AC04DCFEQ27013640-E91005E9-2C09-4B89-9769-14A8610E778AQ27022321-48214828-06E3-4DE3-B68B-B9D8C1A19C80Q27649448-ADE019D6-263C-4854-AAAD-798CF238639AQ27654214-60E7854E-5F1C-4F2B-B203-3BC8008B945FQ27665886-359F834D-C92A-4C55-B6E6-83F8B4491CCDQ27676066-CE62FC9B-50FD-4FCF-9D04-B1ECC877737BQ27677883-6F278C75-B278-4CD6-90D2-3C2EA0BF1F53Q27682550-92636884-8D5D-4379-9CCA-85004198AD95Q27684692-FF5293F5-36FC-4B2D-862B-22615666302FQ27690917-1D8E5650-26A2-49DA-AD43-64C4B5DEE390Q28082915-6F499B61-6180-46E7-A587-9E04148E65AEQ28270261-B27CFA1C-6491-4616-99AC-6D810709F726Q28283802-B7F66645-AB93-43E2-90BC-766C215C5DCFQ28308105-AE90C8E1-F4EF-4E59-B336-DDD329DBAF6AQ28396462-A9E99379-603D-4875-A767-3ADC39115F3AQ28543104-7777CFAD-5B90-4A5E-8493-24BCB3D30C29Q28646993-BAAA0D6F-D875-45E5-911D-C4A796DED8D0Q28728956-AA70DD28-19D1-449E-A3EB-8D080C5E72AFQ28749033-96CA2F8F-086A-4F04-BA34-524F6BE5C792Q28749085-8F5E212B-FA93-4024-9C87-93E7A0A6D94AQ30157932-AAC84E7B-70C7-42D1-8B92-0D00012DD11AQ30250972-22EA4B2A-D816-43E1-BF7E-942855F3DFBEQ30360964-F8740FF8-1575-46CE-B142-9C5181D1AB0EQ30362113-4A3F11B6-017B-4D79-B78A-34DA6548CD9EQ30377654-972B1341-5730-4C28-80E7-4C63503091C2Q30384877-B363BF3D-710B-4D7B-8795-60E7A4A6C3B4Q30394338-1185410B-6DF7-42CB-ABFB-5AC5B81AD629Q30418309-D0A9AAE6-4758-4933-9F4E-822BD8D2A294Q30421637-129C5157-CC29-45A1-8F8D-428018604723Q30482656-5F6AE24B-1E48-4886-8276-0DD0ADFD7444
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Potent antibody therapeutics by design.
@ast
Potent antibody therapeutics by design.
@en
type
label
Potent antibody therapeutics by design.
@ast
Potent antibody therapeutics by design.
@en
prefLabel
Potent antibody therapeutics by design.
@ast
Potent antibody therapeutics by design.
@en
P2860
P356
P1476
Potent antibody therapeutics by design.
@en
P2093
Paul J Carter
P2860
P304
P356
10.1038/NRI1837
P577
2006-05-01T00:00:00Z